|
|
|
|
|
|
|
|
|
|
|
|
|
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM (A) THE
ACCOMPANYING FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH (B) FINANCIAL STATEMENTS.
</LEGEND>
<CIK> 0000929547
<NAME> INKINE PHARMACEUTICAL
<MULTIPLIER> 1,000
<CURRENCY> US DOLLARS
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JUL-01-2000
<PERIOD-END> SEP-30-2000
<EXCHANGE-RATE> 1
<CASH> 5,587
<SECURITIES> 9,385
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 15,028
<PP&E> 523
<DEPRECIATION> 212
<TOTAL-ASSETS> 15,372
<CURRENT-LIABILITIES> 1,619
<BONDS> 0
0
0
<COMMON> 3
<OTHER-SE> 13,750
<TOTAL-LIABILITY-AND-EQUITY> 15,372
<SALES> 0
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 8,485
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 6
<INCOME-PRETAX> (8,225)
<INCOME-TAX> 0
<INCOME-CONTINUING> (8,225)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (8,225)
<EPS-BASIC> (.25)
<EPS-DILUTED> (.25)
</TABLE>
|
|